Overview
Bioxodes develops an innovative pipeline in thrombo-inflammation with BIOX-101 as its lead candidate. The drug has a unique mechanism of action targeting neutrophils and coagulation factors (FXIIa, FXIa) for the prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients.
Key people
In the news
- 𝐁𝐈𝐎𝐗-101 𝐚𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞𝐝 𝐫𝐞𝐜𝐨𝐯𝐞𝐫𝐲 𝐚𝐧𝐝 𝐫𝐞𝐝𝐮𝐜𝐞𝐝 𝐬𝐞𝐜𝐨𝐧𝐝𝐚𝐫𝐲 𝐛𝐫𝐚𝐢𝐧 𝐢𝐧𝐣𝐮𝐫𝐲 𝐚𝐟𝐭𝐞𝐫 𝐢𝐧𝐭𝐫𝐚𝐜𝐞𝐫𝐞𝐛𝐫𝐚𝐥 𝐡𝐞𝐦𝐨𝐫𝐫𝐡𝐚𝐠𝐞 𝐢𝐧 𝐧𝐞𝐰𝐥𝐲 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 𝐩𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐝𝐚𝐭𝐚 Our preclinical data on BIOX-101 in intracerebral hemorrhage (ICH) are published in the peer-reviewed journal 𝐂𝐍𝐒 𝐍𝐞𝐮𝐫𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞 & 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, with Stéphanie Demoulin, PhD, as corresponding author, together with ETAP-Lab and Prof. Denis Vivien at CHU Caen
- 𝐄𝐯𝐞𝐫𝐲 2 𝐬𝐞𝐜𝐨𝐧𝐝𝐬, 𝐬𝐨𝐦𝐞𝐨𝐧𝐞, 𝐬𝐨𝐦𝐞𝐰𝐡𝐞𝐫𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐰𝐨𝐫𝐥𝐝 𝐬𝐮𝐟𝐟𝐞𝐫𝐬 𝐚 𝐬𝐭𝐫𝐨𝐤𝐞. Yesterday was 𝐖𝐨𝐫𝐥𝐝 𝐒𝐭𝐫𝐨𝐤𝐞 𝐃𝐚𝐲, a reminder of the devastating impact stroke continues to have on patients, families and healthcare systems worldwide. While recognizing the signs of stroke and acting quickly remains essential, significant unmet needs persist. This is particularly true for intracerebral hemorrhage (ICH), the deadliest form of stroke and a condition for which no approved treatment
- Chief Executive Officer Marc Dechamps will be speaking at the 4𝐭𝐡 𝐁𝐞𝐧𝐞𝐥𝐮𝐱 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦, bringing together leaders from biotech, pharma, investment and innovation to discuss the future of drug development. This year's theme,"𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐢𝐧𝐠 𝐭𝐡𝐞 𝐖𝐚𝐲 𝐖𝐞 𝐓𝐡𝐢𝐧𝐤", will explore new perspectives on advancing drug development and translating scientific innovation into therapies that can benefit patients. At Bioxodes, we are applying that mindset to intracerebral
- 𝐁𝐈𝐑𝐂𝐇 𝐏𝐡𝐚𝐬𝐞 2𝐚 𝐝𝐚𝐭𝐚 𝐬𝐡𝐨𝐰 𝐬𝐭𝐚𝐭𝐢𝐬𝐭𝐢𝐜𝐚𝐥𝐥𝐲 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐫𝐞𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐢𝐧 𝐩𝐞𝐫𝐢𝐡𝐞𝐦𝐚𝐭𝐨𝐦𝐚𝐥 𝐞𝐝𝐞𝐦𝐚 𝐠𝐫𝐨𝐰𝐭𝐡 𝐰𝐢𝐭𝐡 𝐁𝐈𝐎𝐗-101 𝐢𝐧 𝐢𝐧𝐭𝐫𝐚𝐜𝐞𝐫𝐞𝐛𝐫𝐚𝐥 𝐡𝐞𝐦𝐨𝐫𝐫𝐡𝐚𝐠𝐞 Bioxodes today presented new imaging analyses and one-year functional outcomes from the BIRCH Phase 2a trial of BIOX-101 in a Late-Breaking Science oral presentation at the 18𝐭𝐡 𝐖𝐨𝐫𝐥𝐝 𝐒𝐭𝐫𝐨𝐤𝐞 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 (#WSC2026) in Seoul, given by Dr. Dimitri Hemelsoet,
- 𝐓𝐢𝐦𝐞 𝐢𝐬 𝐛𝐫𝐚𝐢𝐧." As Bioxodes CEO Marc Dechamps emphasized last week at the 1𝐬𝐭 𝐀𝐧𝐧𝐮𝐚𝐥 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐈𝐦𝐩𝐚𝐜𝐭 𝐒𝐮𝐦𝐦𝐢𝐭 in Basel, every minute matters in stroke, but so does what happens after the initial event. Marc joined 𝐓𝐡𝐞 𝐍𝐞𝐱𝐭 𝐅𝐫𝐨𝐧𝐭𝐢𝐞𝐫 𝐢𝐧 𝐒𝐭𝐫𝐨𝐤𝐞 𝐂𝐚𝐫𝐞: 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, 𝐃𝐞𝐯𝐢𝐜𝐞𝐬 & 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 panel for a wide-ranging discussion on where stroke care is heading. 𝐓𝐡𝐫𝐞𝐞 𝐤𝐞𝐲 𝐭𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬:
- Last week, Maria Fonseca joined #BostonBiotechWeek and #RESI in Boston on behalf of Obulytix, connecting with investors, biotech entrepreneurs, researchers, and industry leaders from across the life sciences ecosystem. A particular highlight was sharing the experience with the Belgian biotech delegation and exchanging perspectives on the challenges and opportunities of translating innovation from bench to patient in our local ecosystem. At RESI, organized by Life Science Nation, we gained valuable insights into US and
- 𝐏𝐑𝐄𝐒𝐒 𝐑𝐄𝐋𝐄𝐀𝐒𝐄: 𝐓𝐡𝐞 𝐟𝐢𝐧𝐚𝐥 𝐁𝐈𝐑𝐂𝐇 𝐝𝐚𝐭𝐚 𝐡𝐚𝐯𝐞 𝐛𝐞𝐞𝐧 𝐬𝐞𝐥𝐞𝐜𝐭𝐞𝐝 𝐟𝐨𝐫 𝐚 𝐋𝐚𝐭𝐞-𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐨𝐫𝐚𝐥 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐚𝐭 𝐭𝐡𝐞 18𝐭𝐡 𝐖𝐨𝐫𝐥𝐝 𝐒𝐭𝐫𝐨𝐤𝐞 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 𝐢𝐧 𝐒𝐞𝐨𝐮𝐥, 𝐒𝐨𝐮𝐭𝐡 𝐊𝐨𝐫𝐞𝐚. The final Phase 2a data show statistically significant improvements with BIOX-101 across multiple secondary endpoints in acute intracerebral hemorrhage (ICH). They build on the positive results reported earlier this year and cover safety, imaging and
- 𝐀 𝐠𝐫𝐨𝐮𝐩 𝐨𝐟 𝐥𝐞𝐚𝐝𝐢𝐧𝐠 𝐬𝐭𝐫𝐨𝐤𝐞 𝐞𝐱𝐩𝐞𝐫𝐭𝐬 𝐢𝐬 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐢𝐧𝐠 𝐁𝐢𝐨𝐱𝐨𝐝𝐞𝐬' 𝐰𝐨𝐫𝐤 𝐢𝐧 𝐢𝐧𝐭𝐫𝐚𝐜𝐞𝐫𝐞𝐛𝐫𝐚𝐥 𝐡𝐞𝐦𝐨𝐫𝐫𝐡𝐚𝐠𝐞. 𝐌𝐞𝐞𝐭 𝐭𝐡𝐞 𝐁𝐢𝐨𝐱𝐨𝐝𝐞𝐬 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐀𝐝𝐯𝐢𝐬𝐨𝐫𝐲 𝐁𝐨𝐚𝐫𝐝. Today, we introduce Dr. Else Charlotte Sandset, consultant neurologist and Chair of Stroke and General Neurology at Oslo University Hospital Ullevål. Her research focuses on acute stroke care, particularly blood pressure management and prehospital stroke pathways. She
Something wrong or missing? Send an update. Fixed within 24 hours.